Table II.
Annual indirect costs.
| Author, year | Country | Results (Euro, 2012) |
|---|---|---|
| Carls, 2009 (21) | USA | SLE group vs. matched control group |
| Absenteeism costs in 12-mo study period | ||
| €3335 vs. €3863 | ||
| Short term disability costs in 12-mo study period | ||
| €2157 vs. €1019 | ||
| Patients without nephritis vs. matched control group | ||
| €5492 vs. €3935 | ||
| Patients with nephritis vs. matched control group | ||
| €5582 vs. €4747 | ||
| Zhu, 2009 (22) | Hong Kong | Patients with flares vs. patients without flares |
| €4568 vs. €5361 | ||
| Campbell, 2009 (24) | USA | SLE patients vs. matched control group |
| Average salary loss for all participants at risk of job loss | ||
| €5398 vs. €791 | ||
| Zhu, Tarn (25) | Hong Kong | SLE patients |
| €4705 | ||
| 0 NPSLE: €4091 | ||
| ≥1 NPSLE: €6357 | ||
| With seizure: €6154 | ||
| With CVD: €5127 | ||
| With headache: €2523 | ||
| Clarke, 2008 (26) | Canada | Patients without renal damage vs. with renal damage |
| SLICC 0= €56,290 | ||
| SLICC 1= €63,234 | ||
| SLICC 2= €60,011 | ||
| SLICC 3= €66,076 | ||
| Panopalis, 2007 (28) | USA | SLE patients |
| USA: €17,059 | ||
| Canada: €11,586 | ||
| UK: €13,490 |